A phase I study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose of BMS-938790 in healthy subjects
Latest Information Update: 08 Sep 2015
Price :
$35 *
At a glance
- Drugs BMS 938790 (Primary)
- Indications Cancer; Immunological disorders
- Focus Pharmacodynamics; Pharmacokinetics
- 08 Sep 2015 New trial record